Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.49 |
| ▸ | TOP2A | P11388 | 2/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12130956 | 0.91 | GSK3B (0.58) | GSK3BCNR1CNR2 | |
| SCHEMBL1343054 | 0.91 | GSK3B (0.58) | GSK3BCNR1CNR2 | |
| SCHEMBL12130954 | 0.88 | STAT3 (0.48) | GSK3BTOP2ATOP2BCNR1CNR2 | |
| SCHEMBL1345047 | 0.88 | STAT3 (0.48) | GSK3BTOP2ATOP2BCNR1CNR2 | |
| SCHEMBL1345178 | 0.88 | GSK3B (0.51) | GSK3BTOP2ATOP2BCNR1CNR2 | |
| SCHEMBL5473835 | 0.82 | TOP2A (0.49) | GSK3BTOP2ATOP2BCNR1CNR2 | |
| SCHEMBL5482130 | 0.82 | TOP2A (0.49) | GSK3BTOP2ATOP2BCNR1CNR2 | |
| SCHEMBL12130952 | 0.80 | GSK3B (0.49) | GSK3BCNR1CNR2STAT3 | |
| SCHEMBL1345172 | 0.80 | GSK3B (0.49) | GSK3BCNR1CNR2STAT3 | |
| SCHEMBL12130953 | 0.78 | GSK3B (0.43) | GSK3BCNR1CNR2STAT3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-2383271-A1 | Aminoquinolones as GSK-3 Inhibitors | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885TOP2A 205/4885TOP2B 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.